Related Experiment Video
Updated: Aug 11, 2025
04:17
Author Spotlight: Advancing Cellular and Protein Engineering to Control Biological Functions and Develop Novel Therapies
Published on: September 27, 2024
759
Hyaluronidase Availability in Emergency Rooms: A Statewide Analysis.
Daniel P Zaki1, Idean Roohani2, Joseph M Firriolo3
1University of Arizona College of Medicine, Tucson, Arizona, USA.
Facial Plastic Surgery & Aesthetic Medicine
|February 7, 2023
Summary
Many California emergency rooms lack immediate access to hyaluronidase (HYAL), an essential treatment for hyaluronic acid filler complications. This unavailability poses a significant risk to patient safety in managing ischemic events.
Area of Science:
- Emergency Medicine
- Dermatology
- Plastic Surgery
Background:
- Hyaluronic acid (HA) fillers are popular cosmetic procedures.
- Ischemic complications like blindness and tissue necrosis can occur with HA fillers.
- Immediate administration of hyaluronidase (HYAL) is critical for managing HA filler-induced vascular events.
Purpose of the Study:
- To assess the immediate availability of hyaluronidase (HYAL) in California emergency rooms (ERs).
- To identify factors influencing HYAL accessibility in ER settings.
- To evaluate the implications of HYAL unavailability for patient safety.
Main Methods:
- A telephone survey was conducted across all California ERs.
- Inquired about the immediate availability of hyaluronidase (HYAL).
- Response rate was 89.7% (296 out of 330 ERs).
Main Results:
- 45.6% of surveyed California ERs reported no immediate access to hyaluronidase (HYAL).
- HYAL availability correlated positively with adult trauma center status (Level I-III), pediatric trauma center status, children's hospital designation, higher bed counts, and geographic region.
- Statistical significance was observed for all positive associations (p < 0.05).
Conclusions:
- Hyaluronidase (HYAL) availability in California ERs is inconsistent.
- Lack of immediate HYAL access presents a potential risk to patient safety.
- Further investigation into improving ER preparedness for HA filler complications is warranted.
